Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
18 Mar 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/late-breaking-phase-3-data-at-aad-2023-show-oral-investigational-medicine-deuruxolitinib-significantly-improved-scalp-hair-regrowth-in-alopecia-areata-301775606.html
07 Mar 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sun-pharma-completes-acquisition-of-concert-pharmaceuticals-301763327.html
15 Feb 2023
// BUSINESSWIRE
15 Feb 2023
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/concert-persuades-fda-keep-breakthrough-tag-alopecia-therapy-despite-lillys-arrival
20 Jan 2023
// REUTERS
https://www.reuters.com/markets/deals/indias-sun-pharma-acquire-us-based-concert-576-mln-2023-01-19/
21 Nov 2022
// BUSINESSWIRE
Details:
Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Dermatology Portfolio.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition June 03, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $576.0 million
Deal Type : Acquisition
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Details : Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Der...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : $576.0 million
June 03, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2023
Details:
Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition January 19, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $576.0 million
Deal Type : Acquisition
Details : Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in lat...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : $576.0 million
January 19, 2023
Details:
Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2022
Details:
Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Terran Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 03, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Terran Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 03, 2022
Details:
The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp ...
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2022
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients...
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Details:
The publication reports clinically meaningful and statistically significant scalp hair regrowth after 24 weeks of treatment with CTP-543 (deuruxolitinib) in both the 8 mg twice-daily and 12 mg twice-daily dose groups in patients with alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 06, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata publis...
Details : The publication reports clinically meaningful and statistically significant scalp hair regrowth after 24 weeks of treatment with CTP-543 (deuruxolitinib) in both the 8 mg twice-daily and 12 mg twice-daily dose groups in patients with alopecia areata.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Details:
CTP-543 (deuterated ruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. The safety profile seen with CTP-543 in THRIVE-AA1 was consistent with previous studies.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTP-543 (deuterated ruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. The safety profile seen with CTP-543 in THRIVE-AA1 was consistent with previous studies.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Details:
Phase 3 trial for CTP-543 (Deuterated Ruxolitinib) THRIVE-AA clinical program, now fully enrolled and progressing toward completion, our focus will be on efficiently moving to data readout and preparing our New Drug Application.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 trial for CTP-543 (Deuterated Ruxolitinib) THRIVE-AA clinical program, now fully enrolled and progressing toward completion, our focus will be on efficiently moving to data readout and preparing our New Drug Application.
Product Name : CTP-543
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2022
ABOUT THIS PAGE